5 Leading Vendors in Human Vaccines Market
15 Oct 2018 • by Natalie Aster
LONDON – Nowadays, billions of people from pole to pole are successfully protected from a range of diseases through vaccination. Vaccines are one of the most powerful and cost-effective health interventions existing in the world. Each year, vaccines help to save lives of approximately 3,000,000 children as well as significantly reduces the prevalence of numerous diseases, disability, and death rates across the globe.
Human Vaccines Market Overview
The world’s human vaccines market has demonstrated a robust upturn during the recent years and is anticipated to continue following an upward trajectory in the coming years, registering a CAGR of 10-12%. Steady growth in this market is encouraged to a large extent by the adding of some pediatric vaccines to the national immunisation programs (NIPs) of a great number of countries. Besides, the enhancing public awareness about the necessity and benefits of vaccination, expanding vaccination coverage around the globe, and increasing support from government as well as non-government organisations also add considerably to the vaccines market growth. Moreover, the ongoing economic recovery worldwide resulting in higher disposable incomes also acts as the growth engine of the vaccines market. Meanwhile, high R&D costs and strict regulatory arrangements associated with approval processes are viewed as the major restraints of the vaccines market growth.
Presently, preventable human vaccines capture a share of above 94% of the overall human vaccines market and are predicted to keep on growing in the coming years enjoying an impressive CAGR of over 10%. Favourable public-private initiatives aimed at the promotion of vaccination, adoption of pediatric vaccines as a part of NIPs in many countries, and the increasing focus on the emerging regions are some of the key factors predicted to spur growth of this segment in the years ahead.
As for regions, the Americas hold the biggest chunk of the worldwide human vaccines market; this is majorly attributed to the high incidence of cancers and different infectious diseases in Canada, the US, and Latin American countries. In the medium-to-long term, the Americas are likely to maintain the leading position in the human vaccines market, and their share of the global market is poised to reach 45% in 2020.
Leading Manufacturers in Human Vaccines Market
Today, the competition in the world’s human vaccines market is very fierce due to the presence of an array of large and small companies operating on global and local scales. The vendors engaged in the vaccines industry compete on the basis of quality, price, and innovation with a view to expand their market shares. The constantly intensifying competition in the human vaccines domain has resulted in a higher number of M&A deals, whereby larger players acquire or merge smaller ones.
5 leading pharmaceutical companies based on their share of global human vaccines market revenue, 2017
TOP FIVE VENDORS OF HUMAN VACCINES IN 2018:
Established in 1873 in Wellington (New Zealand), GlaxoSmithKline is now one of the biggest vaccine manufacturers around the world headquartered at London (the UK). The company has been among top 5 vaccines manufacturers for many years already. Its annual revenue is estimated at over USD 35 billion. GlaxoSmithKline employs about 1 million professionals. Some of the most popular vaccines manufactured by GlaxoSmithKline include Boostrix, Ambirix, Menjugate, Varilix, and Rabipur.
In 2017, GlaxoSmithKline generated revenues of above USD 6.65 billion in the human vaccines segment and accounted for around 24% of the world’s overall human vaccines market revenues. In 2024, the company’s revenues in the human vaccines segment are likely to exceed USD 10.7 billion, whilst the share of the global market revenues will remain the same.
2. Merck & Co.
Incorporated in 1891, the US-based company Merck & Co. is now one of the leading players in the vaccines segment as well as the overall pharmaceuticals market. Today, it employs around 70 thousand people, and its annuals sales are estimated at nearly USD 40 billion. The list of the top-selling vaccines developed by Merck & Co. comprises Recombivax HB, Gardasil, RotaTeq, Zostavax, and Varivax.
In 2017, the human vaccines sales revenue generated by Merck & Co. totaled over USD 6.54 billion, and in 2024 it is projected to cross USD 9.39 billion. The Company’s share of the global human vaccines market revenue is poised to decrease slightly from 23.6% in 2017 to 21.1% in 2024.
The third position on the list of the global leading human vaccines vendors is held by the US-based company Pfizer, which was established in 1849. This company consistently ranks amid the top 10 manufacturers of vaccines in the world. Pfizer boasts a global presence and currently employs almost 98 thousand workers. The company’s annual revenue is estimated at approximately USD 50 billion. The prominent Pfizer’s vaccine brands include NeisVac-C, Prevnar, Mencevax, Trumenba, and Nimenrix.
Pfizer’s revenue generated by the sale of human vaccines surpassed USD 6 billion in 2017 and is anticipated to go beyond USD 7.25 billion in 2024. Meantime, Prizer’s share of the world’s human vaccines market revenue is set to decline considerably in the coming years: from 21.7% in 2017 to 16.3% in 2024.
Another leading manufacturer of human vaccines is the French company Sanofi. It was founded in 1973. Now the company employs more than 110 thousand professionals all over the globe. Sanofi is well-known worldwide for R&D of highly-effective vaccines for babies. The company’s annual revenue exceeds USD 40 billion. Sanofi’s top-selling vaccines comprise Adacel-Polio, Act-HIB, Pediacel, Quadracel, ViVAXIM, and YF-VAX.
In 2017, Sanofi generated more than USD 5.76 billion on the sale of human vaccines, the company’s revenue in this segment is poised to amount to USD 8.13 billion in 2024. Meanwhile, Sanofi’s share of the overall revenue of the world’s human vaccines market is slated to decrease from 20.8% in 2017 to 18.2% in 2024.
CSL is an established player in the human vaccines market. The company was founded in 1916 and is headquartered in Melbourne (Australia). It focuses on the R&D of a wide range of vaccines for the prevention of various serious life-threatening diseases. Presently, CSL employs over 20 thousand people across 60 countries. The company’s annual revenue is estimated at around USD 7 billion. The most popular vaccines manufactured by CSL include Fluvax, Pheumovax, Panvax, Varivax, and Tet-Tox.
CSL’s revenue generated in the human vaccines sector totaled some USD 835 million in 2017 and is expected to cross USD 1.06 billion in the year 2024. The company’s share of the total revenue of the global human vaccines market is slated to decline from 3% in 2017 to 2.4% in 2024.
© MarketPublishers.com, 2018